Novartis AG
AMORPHOUS NANOSTRUCTURED PHARMACEUTICAL MATERIALS

Abstract:

Embodiments of the invention relate to a process for enhancing the bioavailability of poorly soluble active ingredients, and to formulations of powders made by such process. Embodiments of the invention comprise a spinodal decomposition method by which low, sparingly or poorly-soluble materials are converted to amorphous materials with, improved or enhanced solubility suitable for therapeutic use. The powder formulations are useful for the treatment of diseases and conditions, especially respiratory diseases and conditions.